Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration approved Bausch + Lomb’s new drug application for bromfenac ophthalmic ...
U.S. Debut for New Once-Daily PROLENSA™ (bromfenac ophthalmic solution) 0.07 percent Special Cataract and Refractive Surgical Suites on Display, with Featured Demonstrations of the VICTUS™ Femtosecond ...
ISTA Plans to File PROLENSA New Drug Application in First Quarter 2012 PROLENSA's Formulation Covered by Pending Patent Applications IRVINE, CA, Oct 13, 2011 (MARKETWIRE via COMTEX) -- ISTA ...
In October, ISTA reported statistically significant Phase 3 results for its product candidate, PROLENSA™ (bromfenac ophthalmic solution), which incorporates this proprietary formulation of bromfenac.
New Once-Daily NSAID Indicated for Treatment of Postoperative Inflammation and Reduction of Ocular Pain Following Cataract Surgery PROLENSA provides powerful and rapid resolution of inflammation and ...
PROLENSA (bromfenac) ophthalmic solution The FDA has approved Bausch & Lomb's New Drug Application for Prolensa ophthalmic solution, which treats post-operative inflammation and reduces ocular pain in ...
Please provide your email address to receive an email when new articles are posted on . IRVINE, Calif. — Two phase 3 studies on Prolensa (bromfenac ophthalmic solution, Ista Pharmaceuticals) produced ...
The United States Patent and Trademark Office (US PTO) has granted Patent No. 8,129,431 to ISTA Pharmaceuticals' once-daily topical non-steroidal anti-inflammatory product Prolensa (bromfenac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results